REpositioning of Medications IN Dementia (REMIND)

Study identification

• EU PAS number:
  EUPAS1000000484
• Study ID:
  1000000484
• Official title and acronym:
  REpositioning of Medications IN Dementia (REMIND)
• DARWIN EU® study:
  No
• Study countries:
  France
• Study description:
  Despite extensive research and funding, Alzheimer's disease and related disorders (ADRD) currently have no curative or preventive treatment. Numerous treatments—including oral medicines, vaccines and immunotherapy—have been developed to treat symptoms or slow the progression of Alzheimer's disease, but few have been granted market authorization and none offer a satisfactory benefit/risk ratio. ; Medication repositioning studies are an innovative approach to accelerate both identification and testing of potentially effective medications already on the market by re-analyzing real-world data. Medication repositioning studies can use in vitro, in silico, and in vivo methods to identify medications candidates which, in a second step, must be evaluated using appropriate methods to demonstrate a causal relationship between drug and disease. ; A critical hurdle in drug development, phase III clinical trials typically take the form of randomized controlled trials (RCT), the gold standard for questions of causality; however, RCTs are not well suited to answer questions requiring a long follow-up, such as questions surrounding the prevention of ADRD, a disease with a long lag time (>10 years). Nevertheless, innovative methods such as target trial emulation enable causality to be evaluated using observational data which has the long follow-up and low drop-out necessary. Large real-world databases such as the French National Health Data System (SNDS), which follows individuals from birth or immigration to death or emigration, remain largely under-exploited in the field of medication repositioning. ; Using data from the SNDS, the REMIND study aims to identify approved medications that may prevent ADRD and to test the comparative effectiveness of reducing ADRD incidence versus active controls. An exploratory aim is to identify medication combinations associated with ADRD, which has been largely unstudied and will serve to generate hypotheses for further research.
• Study status:
  Planned

Research institutions and networks

Institutions

Bordeaux PharmacoEpi, University of Bordeaux

France

INSERM

France

Harvard T.H. Chan School of Public Health
National Institute of Aging and National Institute of Health
Rutgers Institute for Health, Health Care Policy and Aging Research
Fondation Bordeaux Université

Study timelines

Date when funding contract was signed

Planned: 01/01/2025

Actual: 14/01/2025

Study start date

Planned: 01/04/2025

Data analysis start date

Planned: 01/08/2025

Date of final study report

Planned: 31/12/2027

Sources of funding

Other

More details on funding

AXA research sponsorship

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable